Tag:
Pfizer
Latest Headlines
Latest Headlines
The return of M&A?
Investment bankers are hardly sitting around watching YouTube and playing computer golf. They're working on some big deals, like the IBM purchase of SPSS. We might see more fruits from that labor in the second half of the year, notes Business Week .
This is indeed a decent time for strategi
When will deal volume turn up?
Investment bankers tend to be an optimistic lot, convinced that the next big deal is right around the corner. There's hope but not a whole lot more right now. Sure, we've seen some big pharmaceutical deals--Pfizer and Wyeth, Merck and Schering Plough--and the financing situation may have marginall
Wachtell Lipton on top of merger world
There are a lot fewer deals these days. And we've seen some massive change when it comes to investment banks and the mergers and acquisitions league tables. To that list, we can now add law firms. After a tumultuous year, Wachtell, Lipton, Rosen and Katz has landed on top.
Bloomberg report
Big winners in M&A shakeout
Mergers and acquisitions are far from dead. Investment bankers, the ones that are still employed anyway, have plenty to do. In fact, we're seeing some interesting market-share dynamics at work. Bloomberg notes that Pfizer's purchase of Wyeth was a big win for Goldman Sachs and JPMorgan (both a
Morgan Stanley tops M&A table
Advisory work on two big drug deals pushed Morgan Stanley to the top of the M&A league tables for the first quarter. The bank advised Wyeth on its $64.5 billion purchase by Pfizer and Schering Plough on its $46 billion takeover by Merck, Reuters notes. Such work allowed it to leap to the t
